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Heart failure is a leading cause of morbidity and mortality
in the developed world. Cardiac injury with a signiﬁcant
loss of cardiomyocytes usually leads to a common ﬁnal
pathway of cardiac pathological remodelling that includes
ﬁbrosis, and the development and progression of heart
failure. The treatment of chronic heart failure generally
relies on strategies designed to target and limit cardiac
ischemia, additional tissue damage, pathological cardiac
remodelling, or hemodynamic impairment and cardiac
dyssynchrony. Moreover, understanding of the pathways that
chauﬀeurpathologicalremodellingasopposedtomyocardial
repair and regeneration in the failing heart still remains
challenging. The identiﬁcation of stem cells has, however,
opened new prospects for the development of cell-based
regenerative medicine [1]. Indeed, the heart may contain
a pool of resident or circulation-derived stem cells, but,
following injury, these endogenous cells are not suﬃciently
regenerative to fully repair-damaged myocardium [2]. To
overcome this insuﬃciency, treatments have been proposed
with exogenous stem cells or their progeny, which may
reduce pathological processes in the damaged heart and
improve cardiac tissue regeneration in mice and humans.
Despite concerted eﬀorts to treat damaged myocardium
through cell transplantation, it remains a matter of debate
whether the delivery of stem cells or stem cell progeny
contributes principally to new cardiac tissue formation, to
the activation of endogenous repair mechanisms, or to the
modulation of inﬂammatory processes [3]. More impor-
tantly, stem cell-based therapies have resulted in improved
cardiacfunction,andthedevelopmentofthislineofresearch
represents a new frontier in modern cardiovascular research.
In this special issue of Stem Cells International, we have
assembledaseriesoforiginalmanuscriptsandreviewarticles
dealing with this research frontier. The articles describe a
variety of novel strategies to obtain cells for cardiac repair or
regeneration and discuss current eﬀorts, available tools, and
new methods for stem cell-based therapies.
Pluripotent stem cells represent one potential source for
stem cell-based therapy in the failing heart [4]; however,
this kind of therapy has some serious limitations, ranging
from ethical issues in humans to the degree of heterogeneity
found in cultures of “puriﬁed” embryonic stem cell-derived
cardiomyocytes (ESC-CMs). Following injection into heart,
previous studies demonstrated that ESC-CMs form grafts
that may mediate long-term recovery of global and regional
myocardial contractile function following infarction. In this
issue, K. R. Boheler et al. [5] speciﬁcally addressed the
question of developmental state and showed that immature
hypoxia-resistant ESC-CMs can be isolated in mass in vitro.
The authors suggested that the use of immature proliferating
CMs that do not seem to form tumors in vivo may
serve as a source of innately hypoxia-resistant CMs useful
in the treatment of ischemic cardiac disorders. Such an
approach might become a viable strategy for treating human
cardiac disease states and injuries in the future; however,
several obstacles still need to be resolved, including potential
immunological responses, safety, and durable improvement
of cardiac function in large animal models.2 Stem Cells International
Inaseparatepaper,S.Schmitteckertetal.[6]proposethe
transcription factor Lbx1 as new marker of diﬀerentiating
ESC-CMs. Lbx1 plays a role in the migration of muscle
progenitor cells in limb buds and determines neuronal
diﬀerentiation processes [7, 8]. Since Lbx1 was largely
expressed in diﬀerentiating ESC-CMs, Lbx1 might represent
a novel tool for the identiﬁcation of proper cell source
to induce the reparative processes in the injured heart.
Moreover, this ﬁnding may provide a model system of Lbx1
target genes and signaling pathways involved in early heart
failure caused by Lbx1 inactivation.
An entirely new vision of stem cell-based therapy was
presented by S. Liebau et al. [9]. In this paper, the authors
focused on calcium-activated potassium channels (SKCas)
as important inducers of stem cell diﬀerentiation. SKCas are
involved in cardiac pacemaker-cell development from ESCs
and morphological shaping of neural stem cells [10, 11].
SKCas are also important modulators of the cytoskeleton
rearrangement [12]. Previously, these authors showed that
increased SKCas channel activity resulted in a strong and
fast diﬀerentiation of pluripotent cells followed by a cell-
fate determination into the cardiac lineage, mainly with
a phenotype of cardiac pacemaker-like cells derived from
ESC and iPS cells [13]. Here, this group reported the
successful generation and characterization of a murine ESC
line overexpressing the subtype 4 of SKCas channels in a
doxycycline-dependent manner. Overexpression of SKCas4
was increased in cardiac and pacemaker-like cells suggesting
SKCas4 as a unique tool to characterize the diﬀerentiation
of pluripotent cells into cardiac phenotypes. SKCas channel-
mediated stem cell diﬀerentiation might also be applicable to
the human system.
Although substantial eﬀorts have been made to develop
therapeutic strategies with stem cells to regenerate injured
heart [3], there is increasing evidence that stem cells
modulate inﬂammatory processes in a paracrine fashion
more so than through direct cardiac tissue regeneration
[14]. Recent ﬁndings have also suggested that the poor
eﬀectiveness of stem cell-based therapies in heart diseases is
a result of nonphysiological microenvironment in aﬀected
cardiac tissue [14, 15]. In particular, inﬂamed myocardium
seems to inhibit the cardio-regenerative capacity of trans-
planted stem cells, while promoting proﬁbrotic processes. A
growingbodyofevidencessuggeststhatthespeciﬁcsignaling
milieu of the aﬀected heart is a key determinant of the
fate and function of stem cells in the myocardium [16].
Coupling modulation of the myocardial microenvironment
with patient-speciﬁc stem cells must, therefore, be consid-
ered before successful stem cell-based therapies of heart
disorders will be achieved. Accordingly, our special issue
oﬀers a comprehensive comparison of diﬀerent sources of
stem cells for heart regeneration in basic science and in
clinical trials. Moreover, there is a discussion of the potential
mechanismsinvolvedinreparativeprocesses[17,18].Finally,
A. Kleger et al. [19] provided a comprehensive review on the
diﬀerential and developmental impact of lysophospholipids
on cardiovascular development, which represents a novel
approach in the ﬁeld and may have relevance for the niche
environment.
Taken together, the compilation of articles in this special
issue of Stem Cells International, discusses the current
state of stem cell-based therapies. The authors address both
experimental and clinical aspects of stem cell research aimed
atimprovingthereparativeprocessesinthefailingheart.The
three research articles speciﬁcally provide novel information
designed either to select for speciﬁc types of stem cells
or to induce the diﬀerentiation of pluripotent cells into
the phenotype of cardiac lineages. The reviews also oﬀer a
broad-based view of current eﬀorts designed to understand
the response of stem cells in a “niche” environment or in
response to speciﬁc molecules. We hope that this issue will
be helpful and interesting for basic researchers as well as for
clinicians interested in or performing experiments designed
to address relevant cardiac issues in regenerative medicine.
Gabriela Kania
Kenneth R. Boheler
Ulf Landmesser
Wojciech Wojakowski
References
[1] P. Anversa, J. Kajstura, and A. Leri, “If I can stop one heart
frombreaking,” Circulation,vol.115,no.7,pp.829–832, 2007.
[2] C. E. Murry, M. H. Soonpaa, H. Reinecke et al., “Haematopoi-
etic stem cells do not transdiﬀerentiate into cardiac myocytes
in myocardial infarcts,” Nature, vol. 428, no. 6983, pp. 664–
668, 2004.
[ 3 ]M .A .L a ﬂ a m m ea n dC .E .M u r r y ,“ R e g e n e r a t i n gt h eh e a r t , ”
Nature Biotechnology, vol. 23, no. 7, pp. 845–856, 2005.
[4] K. R. Boheler, “Pluripotency of human embryonic and
induced pluripotent stem cells for cardiac and vascular regen-
eration,” Thrombosis and Haemostasis, vol. 104, no. 1, pp. 23–
29, 2010.
[5] K. R. Boheler, R. N. Joodi, H. Qiao et al., “Embryonic stem
cell-derived cardiomyocyte heterogeneity and the isolation of
immature and committed cells for cardiac remodeling and
regeneration,” Stem Cells International, vol. 2011, Article ID
214203, 10 pages, 2011.
[ 6 ]S .S c h m i t t e c k e r t ,C .Z i e g l e r ,L .K a r t e s ,a n dA .R o l l e t s c h e k ,
“Transcription factor lbx1 expression in mouse embryonic
stem cell-derived phenotypes,” Stem Cells International, vol.
2011, Article ID 130970, 7 pages, 2011.
[7] H. Brohmann, K. Jagla, and C. Birchmeier, “The role of Lbx1
in migration of muscle precursor cells,” Development, vol. 127,
no. 2, pp. 437–445, 2000.
[8] S. Watanabe, S. Kondo, M. Hayasaka, and K. Hanaoka,
“Functional analysis of homeodomain-containing transcrip-
tion factor Lbx1 in satellite cells of mouse skeletal muscle,”
Journal of Cell Science, vol. 120, no. 23, pp. 4178–4187, 2007.
[9] S. Liebau, M. Tischendorf, D. Ansorge et al., “An inducible
expression system of the calcium-activated potassium channel
4t os t u d yt h ed i ﬀerential impact on embryonic stem cells,”
StemCellsInternational,vol.2011,ArticleID456815,12pages,
2011.
[10] S. Liebau, B. Vaida, C. Proepper et al., “Formation of cellular
projections in neural progenitor cells depends on SK3 channel
activity,” Journal of Neurochemistry, vol. 101, no. 5, pp. 1338–
1350, 2007.Stem Cells International 3
[11] S. Liebau, J. Steinestel, L. Linta et al., “An SK3 channel/
nWASP/Abi-1 complex is involved in early neurogenesis,”
PLoS One, vol. 6, no. 3, Article ID e18148, 2011.
[12] S. J. Kattman, E. D. Adler, and G. M. Keller, “Speciﬁcation of
multipotential cardiovascular progenitor cells during embry-
onic stem cell diﬀerentiation and embryonic development,”
Trends in Cardiovascular Medicine, vol. 17, no. 7, pp. 240–246,
2007.
[ 1 3 ]A .K l e g e r ,T .S e u ﬀerlein, D. Malan et al., “Modulation of
calcium-activated potassium channels induces cardiogenesis
of pluripotent stem cells and enrichment of pacemaker-like
cells,” Circulation, vol. 122, no. 18, pp. 1823–1836, 2010.
[14] J. Endo, M. Sano, J. Fujita et al., “Bone marrow-derived cells
are involved in the pathogenesis of cardiac hypertrophy in
response to pressure overload,” Circulation, vol. 116, no. 10,
pp. 1176–1184, 2007.
[15] M. Bujak and N. G. Frangogiannis, “The role of TGF-β
signaling in myocardial infarction and cardiac remodeling,”
Cardiovascular Research, vol. 74, no. 2, pp. 184–195, 2007.
[16] G. Kania, P. Blyszczuk, and U. Eriksson, “Mechanisms of
cardiac ﬁbrosis in inﬂammatory heart disease,” Trends in
Cardiovascular Medicine, vol. 19, no. 8, pp. 247–252, 2009.
[17] R. Mingliang, Z. Bo, and W. Zhengguo, “Stem cells for cardiac
repair: status, mechanisms, and new strategies,” Stem Cells
International, vol. 2011, Article ID 310928, 8 pages, 2011.
[18] O. M. Villet, A. Siltanen, T. P¨ atil¨ a et al., “Advances in cell
transplantation therapy for diseased myocardium,” Stem Cells
International, vol. 2011, Article ID 679171, 8 pages, 2011.
[19] A. Kleger, S. Liebau, Q. Lin, G. von Wichert, and T.
Seuﬀerlein, “The impact of bioactive lipids on cardiovascular
development,” Stem Cells International, vol. 2011, Article ID
916180, 13 pages, 2011.